在人类疾病的小鼠和非人类灵长类动物模型中，重组抗原诱导的皮肤利什曼病防护作用。
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.
作者信息
Campos-Neto A, Porrozzi R, Greeson K, Coler R N, Webb J R, Seiky Y A, Reed S G, Grimaldi G
机构信息
Infectious Disease Research Institute, Seattle, Washington 98104, USA.
出版信息
Infect Immun. 2001 Jun;69(6):4103-8. doi: 10.1128/IAI.69.6.4103-4108.2001.
Abstract
Leishmaniasis affects approximately 2 million people each year throughout the world. This high incidence is due in part to the lack of an efficacious vaccine. We present evidence that the recombinant leishmanial antigens LmSTI1 and TSA, which we identified and characterized previously, induce excellent protection in both murine and nonhuman primate (rhesus monkey) models of human cutaneous leishmaniasis. The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis.
摘要
利什曼病每年在全球影响约200万人。这种高发病率部分归因于缺乏有效的疫苗。我们提供的证据表明，我们之前鉴定和表征的重组利什曼原虫抗原LmSTI1和TSA，在人类皮肤利什曼病的小鼠和非人类灵长类动物（恒河猴）模型中均能诱导出极佳的保护作用。LmSTI1和TSA在与人类进化关系密切的动物模型中诱导出的显著保护作用，使这种抗原组合成为一种有前景的抗人类利什曼病亚单位疫苗候选物。
相似文献
1
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.
Infect Immun. 2001 Jun;69(6):4103-8. doi: 10.1128/IAI.69.6.4103-4108.2001.
2
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
Infect Immun. 2002 Jun;70(6):2828-36. doi: 10.1128/IAI.70.6.2828-2836.2002.
3
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
Infect Immun. 2002 Aug;70(8):4215-25. doi: 10.1128/IAI.70.8.4215-4225.2002.
4
Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Clin Vaccine Immunol. 2007 Sep;14(9):1173-81. doi: 10.1128/CVI.00060-07. Epub 2007 Jul 11.
5
Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Vaccine. 2004 Sep 28;22(29-30):3865-76. doi: 10.1016/j.vaccine.2004.04.015.
6
Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Exp Parasitol. 2011 Mar;127(3):627-36. doi: 10.1016/j.exppara.2010.12.007. Epub 2010 Dec 25.
7
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.
Infect Immun. 2007 Sep;75(9):4648-54. doi: 10.1128/IAI.00394-07. Epub 2007 Jul 2.
8
Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.
Clin Vaccine Immunol. 2008 Apr;15(4):668-74. doi: 10.1128/CVI.00413-07. Epub 2008 Jan 30.
9
Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Vaccine. 2012 Feb 8;30(7):1357-63. doi: 10.1016/j.vaccine.2011.12.067. Epub 2011 Dec 28.
10
Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
Infect Immun. 2004 Aug;72(8):4521-7. doi: 10.1128/IAI.72.8.4521-4527.2004.
引用本文的文献
1
Immunizing Mice with Influenza Virus-like Particles Expressing the Promastigote Surface Antigen Alleviates Inflammation in Footpad.
Vaccines (Basel). 2024 Jul 18;12(7):793. doi: 10.3390/vaccines12070793.
2
Engineering and design of promising T-cell-based multi-epitope vaccine candidates against leishmaniasis.
Sci Rep. 2023 Nov 8;13(1):19421. doi: 10.1038/s41598-023-46408-1.
3
Screening Novel Vaccine Candidates for by Combining Differential Proteomics and Immunoinformatics Analysis.
Front Immunol. 2022 Jun 23;13:902066. doi: 10.3389/fimmu.2022.902066. eCollection 2022.
4
Anti-mitochondrial Tryparedoxin Peroxidase Monoclonal Antibody-Based Immunohistochemistry for Diagnosis of Cutaneous Leishmaniasis.
Front Microbiol. 2022 Feb 28;12:790906. doi: 10.3389/fmicb.2021.790906. eCollection 2021.
5
Vaccination in Leishmaniasis: A Review Article.
Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35.
6
Effect of Prophylactic Vaccination with the Membrane-Bound Acid Phosphatase Gene of in the Murine Model of Localized Cutaneous Leishmaniasis.
J Immunol Res. 2021 Apr 9;2021:6624246. doi: 10.1155/2021/6624246. eCollection 2021.
7
Non-human primates and immunity.
Cytokine X. 2020 Oct 12;2(4):100038. doi: 10.1016/j.cytox.2020.100038. eCollection 2020 Dec.
8
Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in -infected dogs.
Vaccine X. 2019 Nov 20;4:100048. doi: 10.1016/j.jvacx.2019.100048. eCollection 2020 Apr 9.
9
Construction of a Novel DNA Vaccine Candidate encoding LmSTI1-PpSP42 Fusion Protein from and against Cutaneous Leishmaniasis.
Rep Biochem Mol Biol. 2018 Oct;7(1):67-75.
10
Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice.
PLoS One. 2018 Sep 24;13(9):e0204491. doi: 10.1371/journal.pone.0204491. eCollection 2018.
本文引用的文献
1
Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning.
J Immunol. 2001 Jan 1;166(1):498-505. doi: 10.4049/jimmunol.166.1.498.
2
Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.
Infect Immun. 2001 Jan;69(1):245-51. doi: 10.1128/IAI.69.1.245-251.2001.
3
Cell populations in lesions of cutaneous leishmaniasis of Leishmania (L.) amazonensis- infected rhesus macaques, Macaca mulatta.
Mem Inst Oswaldo Cruz. 2000 Mar-Apr;95(2):209-16. doi: 10.1590/s0074-02762000000200012.
4
Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.
Infect Immun. 2000 Mar;68(3):1328-36. doi: 10.1128/IAI.68.3.1328-1336.2000.
5
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
Nat Med. 2000 Feb;6(2):200-6. doi: 10.1038/72309.
6
Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants.
J Med Primatol. 1999 Aug-Oct;28(4-5):214-23. doi: 10.1111/j.1600-0684.1999.tb00272.x.
7
Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.
J Immunol. 1999 Oct 15;163(8):4481-8.
8
Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi.
Mol Biochem Parasitol. 1999 Aug 20;102(2):249-61. doi: 10.1016/s0166-6851(99)00098-5.
9
Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
Lancet. 1998 May 23;351(9115):1540-3. doi: 10.1016/S0140-6736(98)09552-X.
10
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.
Infect Immun. 1998 Jul;66(7):3279-89. doi: 10.1128/IAI.66.7.3279-3289.1998.
Zotero 插件